Eugenol ameliorates hepatic steatosis and fibrosis by down-regulating SREBP1 gene expression via AMPK-mTOR-p70S6K signaling pathway

Biological and Pharmaceutical Bulletin

Volumn 37, Issue 8, 2014, Pages 1341-1351

  Jo, Hee Kyung ^a   Kim, Go Woon ^a   Jeong, Kyung Ju ^a   Kim, Do Yeon ^a   Chung, Sung Hyun ^a  

^a Kyung Hee University   (South Korea)

Author keywords

AMP activated protein kinase; Eugenol; Fatty liver; Fibrosis; Sterol regulatory element binding protein

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ACTIN; ALPHA-SMOOTH MUSCLE ACTIN, MOUSE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE KINASE; COLLAGEN TYPE 1; EUGENOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; S6 KINASE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TARGET OF RAPAMYCIN KINASE;

ANIMAL; C57BL MOUSE; CELL CULTURE; DOWN REGULATION; DRUG EFFECTS; FATTY LIVER; FIBROSIS; GENETICS; HEPG2 CELL LINE; HUMAN; LIVER; LIVER CELL; MALE; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT;

ACETYL-COA CARBOXYLASE; ACTINS; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE KINASE; CELLS, CULTURED; COLLAGEN TYPE I; DOWN-REGULATION; EUGENOL; FATTY LIVER; FIBROSIS; HEP G2 CELLS; HEPATOCYTES; HUMANS; LIVER; MALE; MICE, INBRED C57BL; PLASMINOGEN ACTIVATOR INHIBITOR 1; RATS, SPRAGUE-DAWLEY; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TOR SERINE-THREONINE KINASES;

EID: 84906751661     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b14-00281     Document Type: Article

References (26)

1. Angulo P. Nonalcoholic fatty liver disease. N. Engl. J. Med., 346, 1221-1231 (2002).
2. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology, 55, 2005-2023 (2012).
3. Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann. Med., 43, 617-649 (2011).
4. Kamatou GP, Vermaak I, Viljoen AM. Eugenol - from the remote Maluku Islands to the international market place: a review of a remarkable and versatile molecule. Molecules, 17, 6953-6981 (2012).
5. Nam H, Kim MM. Eugenol with antioxidant activity inhibits MMP-9 related to metastasis in human fibrosarcoma cells. Food Chem. Toxicol., 55, 106-112 (2013).
6. Tung YT, Chua MT, Wang SY, Chang ST. Anti-inflammation activities of essential oil and its constituents from indigenous cinnamon (Cinnamomum osmophloeum) twigs. Bioresour. Technol., 99, 3908-3913 (2008).
7. Dai JP, Zhao XF, Zeng J, Wan QY, Yang JC, Li WZ, Chen XX, Wang GF, Li KS. Drug screening for autophagy inhibitors based on the dissociation of Beclin1-Bcl2 complex using BiFC technique and mechanism of eugenol on anti-influenza A virus activity. PLoS ONE, 8, e61026 (2013).
8. Jaganathan SK, Supriyanto E. Antiproliferative and molecular mechanism of eugenol-induced apoptosis in cancer cells. Molecules, 17, 6290-6304 (2012).
9. Jaganathan SK, Mazumdar A, Mondhe D, Mandal M. Apoptotic effect of eugenol in human colon cancer cell lines. Cell Biol. Int., 35, 607-615 (2011).
10. Aggarwal BB, Kunnumakkara AB, Harikumar KB, Tharakan ST, Sung B, Anand P. Potential of spice-derived phytochemicals for cancer prevention. Planta Med., 74, 1560-1569 (2008).
11. Wei Y, Wang D, Topczewski F, Pagliassotti MJ. Saturated fatty acids induce endoplasmic reticulum stress and apoptosis independently of ceramide in liver cell. Am. J. Physiol. Endocrinol. Metab., 291, E275-E281 (2006).
12. Seglen PO. Preparation of rat liver cells. 3. Enzymatic requirements for tissue dispersion. Exp. Cell Res., 82, 391-398 (1973).
13. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ, Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology, 41, 1313-1321 (2005).
14. Park KG, Min AK, Koh EH, Kim HS, Kim MO, Park HS, Kim YD, Yoon TS, Jang BK, Hwang JS, Kim JB, Choi HS, Park JY, Lee IK, Lee KU. Alpha-lipoic acid decrease hepatic lipogenesis through adenosine monophosphate-activated protein kinase (AMPK)-dependent and AMPK-independent pathway. Hepatology, 48, 1477-1486 (2008).
15. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J. Clin. Invest., 114, 147-152 (2004).
16. Malaguarmera M, Di Rosa M, Nicoletti F, Malaguarmera L. Molecular mechanisms involved in NAFLD progression. J. Mol. Med., 87, 679-695 (2009).
17. Marcos A, Fisher RA, Ham JM, Olzinski AT, Shiffman ML, Sanyal AJ, Luketic VA, Sterling RK, Olbrisch ME, Posner MP. Selection and outcome of living donors for adult to adult right lobe transplantation. Transplantation, 69, 2410-2415 (2000).
18. Lee JY, Kim KM, Lee SG, Yu E, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ. Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center. J. Hepatol., 47, 239-244 (2007).
19. Younossi Z, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, Srishord M. "The changing face of chronic liver disease (CLD) in the United States: the rising epidemic of non-alcoholic fatty liver disease (NAFLD). Presented at The International Liver Congress.": 'http://www1.easl.eu/easl2011/program/Orals/204.htm'.
20. Morita Y, Ueno T, Sasaki N, Tateishi Y, Nagata E, Kage M, Sata M. Nateglinide is useful for nonalcoholic steatohepatitis (NASH) patients with type 2 diabetes. Hepatogastroenterology, 52, 1338-1343 (2005).
21. Cecchini M, Sassi F, Lauer JA, Lee YY, Guajardo-Barron V, Chisholm D. Tackling of unhealthy diets, physical inactivity, and obesity: health effects and cost-effectiveness. Lancet, 376, 1775-1784 (2010).
22. Barceloux DG. Medical Toxicology of Natural Substances. Foods, Fungi, Medicinal Herbs, Plants and Venomous Animals. Wiley, Hoboken, NJ, U.S.A. (2008).
23. Yogalakshmi B, Viswanathan P, Anuradha CV. Investigation of anti-oxidant, anti-inflammatory and DNA-protective properties of eugenol in thioacetamide-induced liver injury in rats. Toxicology, 268, 204-212 (2010).
24. You M, Matsumoto M, Pacold CM, Cho WK, Crabb DW. The role of AMP-activated protein kinase in the action of ethanol in the liver. Gastroenterology, 127, 1798-1808 (2004).
25. Xu ZJ, Fan JG, Ding XD, Qiao L, Wang GL. Characterization of high-fat, dietinduced, non-alcoholic steatohepatitis with fibrosis in rats. Dig. Dis. Sci., 55, 931-940 (2010).
26. Li L, Chen J, Ni Y, Feng X, Zhao Z, Wang P, Sun J, Yu H, Yan Z, Liu D, Nilius B, Zhu Z. TRPV1 activation prevents nonalcoholic fatty liver through UCP2 upregulation in mice. Pflugers Arch., 463, 727-732 (2012).